[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kymera Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644974","phase-2-a-long-term-study-of-kt-621-administered-orally-to-participants-with-asthma-previously-enrolled-in-a-kt-621-asthma-study-100644974",false,"NCT07677059","A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study","A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study","BREADTH-EXT","Inclusion Criteria:\n\n* Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit.\n* Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.\n* Must agree to contraceptive requirements in compliance with the clinical study and local requirements.\n\nExclusion Criteria:\n\n* Must not have experienced any clinically significant change in health status during the parent study, which, in the opinion of the Investigator, would interfere with participant safety, study evaluations, or compliance with study procedures; or otherwise make the participant unsuitable for participation in this study.\n* Must not have developed an AE during the parent study, that in the opinion of the Investigator or of the Sponsor's Medical Monitor, could indicate that continued treatment may present an unreasonable risk for the participant.\n* Must not have met permanent discontinuation criteria and\u002For permanently discontinued study treatment for any reason during the parent study.\n* Must not be a member of the Sponsor or site's investigational team or their immediate family.\n* Must not be unsuitable to enter the study for any other reason, as judged by the Investigator, including potential risk of noncompliance to study procedures.","ALL","18 Years",{"count":20,"type":21},264,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.",[27],"Asthma (Diagnosis)",[29,30,31,32,33,34,35,36],"KT-621","STAT6","stat6 degrader","targeted protein degrader","Phase 2","phase 2b","OLE","LTE","RECRUITING","2026-06-24",{"date":40,"type":41},"2026-06-30","ACTUAL",{"date":43,"type":21},"2026-07",{"date":45,"type":21},"2028-12",{"name":47,"class":48},"Kymera Therapeutics, Inc.","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100617825","phase-2-a-study-of-kt-621-administered-orally-to-adult-participants-with-moderate-to-severe-eosinophilic-asthma-100617825","NCT07323654","A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma","A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants With Uncontrolled Moderate to Severe Eosinophilic Asthma","BREADTH","Inclusion Criteria:\n\n* Must be 18 years old (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age, inclusive, at the time of signing the ICF.\n* Must have a physician diagnosis of asthma for at least 1 year prior to the Screening visit.\n* Must be on a stable regimen of medium- to high- dose inhaled corticosteroid (ICS), in combination with a long-acting β2-agonist (LABA). The regimen may include additional controller medications used for at least 12 weeks, at a stable dose and regimen, with no change in the dose or frequency of administration for at least 4 weeks prior to the Screening visit and between the Screening and Baseline visits.\n* Must have a pre-bronchodilator FEV1 40 to 80% of predicted normal at the Screening and Baseline visits, prior to randomization.\n* Must have an ACQ-5 score ≥ 1.5 at the Screening and Baseline visits, prior to randomization.\n* Must have a FeNO level of ≥ 25 ppb at the Screening and Baseline visits.\n* Must have a demonstrated evidence of reversible airway obstruction by post-bronchodilator (albuterol\u002Fsalbutamol) reversibility of FEV1 ≥12% and ≥200 mL at Screening.\n* Must have an absolute blood eosinophil count must be ≥ 0.30 × 10\\^9\u002FL at Screening.\n* Must have a documented history of at least 1 asthma exacerbation requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and\u002For hospitalization or an emergency\u002Furgent medical care visit for acute asthma worsening within the past 52 weeks prior to Screening.\n* Must agree to contraceptive requirements in compliance with the clinical study and local requirements.\n* Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.\n\nExclusion Criteria:\n\n* Must not have any clinically significant pulmonary disease other than asthma.\n* Must not have had an asthma exacerbation, requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and\u002For hospitalization or an emergency\u002Furgent medical care visit for acute asthma worsening, at any time from 4 weeks prior to the Screening visit up to and including the Baseline visit.\n* Must not have any other clinically significant disease, condition, or medical history that, in the opinion of the Investigator, would interfere with participant safety, study evaluations, and\u002For study procedures.\n* Must not be pregnant or breastfeeding; must not be a woman planning to become pregnant or breastfeed during the study.\n* Must not have results from clinical laboratory safety tests that are outside the local reference range at Screening.\n* Must not have been dosed with any investigational drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration.\n* Must not have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results.\n* Must not be a current smoker of nicotine\u002Ftobacco as well as non-nicotine products, have a smoking history of ≥ 10 pack years, or use vaping products, including electronic cigarettes. Former smokers with a smoking history of \\\u003C 10 pack years and users of vaping or e-cigarette products must have stopped for at least 26 weeks prior to the Screening visit.\n* Must not have a known sensitivity to any of the components of KT-621.\n* Must not be a member of the investigational team or his\u002Fher immediate family.","75 Years",{"count":20,"type":21},[24],"This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.\n\nThe main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.",[63],"Eosinophilic Asthma",[65,31,66,32,33,34],"kt-621","stat6",{"date":68,"type":41},"2026-06-29",{"date":70,"type":41},"2026-01-28",{"date":72,"type":21},"2027-12",{"name":47,"class":48},58,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":49},"100624642","phase-1-first-in-human-study-of-orally-administered-kt-579-in-healthy-adult-participants-100624642","NCT07412288","First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants","A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-579 in Healthy Adult Participants","Inclusion Criteria:\n\n* Participants with a weight of at least 50 kg if male or 40 kg if female, and a body mass index (BMI) between 18.0 and 32.0 kg\u002Fm² (inclusive) at Screening.\n* Participants must be willing and able to read, understand, and sign an informed consent form (ICF) which includes compliance with requirements and restrictions listed in the ICF and in this protocol.\n* Participants must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Participants who have a clinically relevant history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, ophthalmological, or connective tissue diseases or disorders.\n* Participants who have a clinically relevant surgical history (e.g. surgery of the GI tract that could interfere with the PK of the trial medication) Note: prior appendectomy or cholecystectomy is not exclusionary.\n* Participants with a history of alcohol or substance abuse within the previous 2 years.\n* Participants who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.\n* Participants who test positive for alcohol and drugs of abuse at Screening and on admission to the CRU.\n* Participants who have acute GI symptoms at the time of Screening or on admission to the CRU (e.g. nausea, vomiting, diarrhea, heartburn).\n* Participants whose results from clinical laboratory safety tests are outside the local reference range at Screening and on admission to the CRU.\n* Participants who have previously received KT-579 in another cohort in this study.\n* Participants who have been dosed with any investigational drug or device in a clinical study within 30 days or 5 half-lives (whichever is longer) of KT-579\u002Fplacebo administration.\n* Male participants who do not agree to refrain from sperm donation from admission to the CRU to 90 days after the last dose of study drug.\n* Male participants (and their partners of childbearing potential) and female participants who do not agree to the contraception requirements as specified in the clinical protocol.\n* Female participants who are pregnant, lactating, or breast-feeding or plan to become pregnant (including ova donation) within 30 days of last study drug administration.\n* Female participants with a positive or undetermined pregnancy test at Screening and on admission to the CRU.",true,"55 Years",{"count":85,"type":21},96,[87],"PHASE1","This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.",[90],"Healthy Participants",[92,93,94,32],"Phase 1","IRF5","IRF5 degrader","2026-02-26",{"date":97,"type":41},"2026-02-27",{"date":99,"type":41},"2026-02-23",{"date":101,"type":21},"2026-12",{"name":47,"class":48},""]